---
title: "Disentangling Immune Waning and Viral Evolution on COVID-19 Booster Effectiveness"
id: "medrxiv-22-separating-the-effects-of-immune-waning-and-viral-evolution-on-covid-19-vaccine"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-separating-the-effects-of-immune-waning-and-viral-evolution-on-covid-19-vaccine"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.14.26363077v1?rss=1"
published_at: "2026-09-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Disentangling Immune Waning and Viral Evolution on COVID-19 Booster Effectiveness
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-separating-the-effects-of-immune-waning-and-viral-evolution-on-covid-19-vaccine
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.14.26363077v1?rss=1)
- **Published At:** 2026-09-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint reports a meta-analysis of 44 studies identified via the ViewHub systematic review assessing mRNA booster vaccine effectiveness against severe COVID-19. - Boosters evaluated contained updated immunogens including **XBB.1.5**, **JN.1** and **KP.2** sequences. - The analysis separated two temporal effects on vaccine effectiveness: time since booster (immune waning) and calendar time (viral antigenic drift). - The authors estimate the relative risk of severe disease rises by **9% per month** after booster administration (95% CI 7.4–10.5), attributed to antibody waning. - An additional increase in relative risk of **2.4% per calendar month** (95% CI 1.2–3.6) was attributed to ongoing viral evolution since the vaccine immunogen emerged. - Findings indicate booster effectiveness declines both with elapsed time after vaccination and with calendar time since the immunogen was current, supporting the value of timely vaccine immunogen updates. - The study used only openly available ViewHub data; all data and code will be made available after publication. - The article is a preprint (not peer reviewed) and authors declared no competing interests and adherence to ethical reporting standards. - Funders include Australian National Health and Medical Research Council Investigator Grants and the Medical Research Future Fund. - The authors emphasize the need for regular, timely updating of COVID-19 vaccine immunogens in response to waning immunity and antigenic drift.
## Clinical Analysis & Structured Key Points
Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines | medRxiv Skip to main content Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines View ORCID Profile Wang Jin , Ainslie Mitchell , View ORCID Profile Eva Stadler , View ORCID Profile Charles S.P. Foster , Timothy E. Schlub , View ORCID Profile Miles Philip Davenport , View ORCID Profile Deborah Philip Cromer doi: https://doi.org/10.64898/2026.09.14.26363077 Wang Jin 1 University of New South Wales; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Wang Jin Ainslie Mitchell 2 Kirby Institute, University of New South Wales; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eva Stadler 1 University of New South Wales; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Eva Stadler Charles S.P. Foster 1 University of New South Wales; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Charles S.P. Foster Timothy E. Schlub 3 The University of Sydney; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Miles Philip Davenport 4 Kirby Institute, UNSW Sydney; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Miles Philip Davenport Deborah Philip Cromer 5 UNSW Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Deborah Philip Cromer For correspondence: d.cromer{at}unsw.edu.au Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract The continued evolution of SARS-CoV-2 has led to regular updates of the COVID-19 vaccine immunogen. However, the exact benefits of these updates for vaccine effectiveness in a real world context are difficult to evaluate. We performed a comprehensive meta-analysis of booster vaccine effectiveness in studies identified through the ViewHub systematic review. We integrated evidence from 44 studies reporting on effectiveness of mRNA booster vaccines containing XBB.1.5, JN.1 and KP.2 immunogens to assess the combined impact of booster immunogen, time since vaccination and calendar time at which a study was conducted. We estimate that the relative risk of severe disease increases by 9% [95%CI 7.4-10.5] each month following booster administration, likely due to antibody waning, and by an additional 2.4% [95%CI 1.2-3.6] for each calendar month, likely due to antigenic drift. Our findings show that COVID-19 booster vaccine effectiveness declines both with time after vaccination as well as calendar time since the vaccine immunogen emerged. This reinforces the need for regularly and timely vaccine immunogen updates. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data that were originally located at ViewHub (https://view-hub.org/) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data and code will be made available after publication Funder Information Declared Australian National Health and Medical Research Council Investigator Grants , 2034282 , 2034108 , 2026360 Medical Research Future Fund , MRFF 2016062 , MRFF 2015313 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted September 15, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines Wang Jin , Ainslie Mitchell , Eva Stadler , Charles S.P. Foster , Timothy E. Schlub , Miles Philip Davenport , Deborah Philip Cromer medRxiv 2026.09.14.26363077; doi: https://doi.org/10.64898/2026.09.14.26363077 Share This Article: Copy Citation Tools Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines Wang Jin , Ainslie Mitchell , Eva Stadler , Charles S.P. Foster , Timothy E. Schlub , Miles Philip Davenport , Deborah Philip Cromer medRxiv 2026.09.14.26363077; doi: https://doi.org/10.64898/2026.09.14.26363077 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Public and Global Health Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (901) Anesthesia (331) Cardiovascular Medicine (4814) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1627) Epidemiology (15945) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7047) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5045) Health Policy (1434) Health Systems and Quality Improvement (1766) Hematology (585) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16291) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (154) Nephrology (723) Neurology (7273) Nursing (366) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3608) Ophthalmology (1051) Orthopedics (397) Otolaryngology (456) Pain Medicine (470) Palliative Medicine (139) Pathology (707) Pediatrics (1798) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5896) Public and Global Health (9753) Radiology and Imaging (2421) Rehabilitation Medicine and Physical Therapy (1451) Respiratory Medicine (1248) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (776) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)
- [Study says purer fentanyl won’t by itself explain U.S. overdose death decline](https://medichelpline.com/clinical-feed/stat-news-2-purer-fentanyl-won-t-solve-the-u-s-overdose-death-crisis-study-says.md)
- [Projected preventable pneumococcal disease in Japanese adults ≥65: PCV21 versus PCV20](https://medichelpline.com/clinical-feed/medrxiv-15-estimation-of-preventable-pneumococcal-disease-burden-by-pcv20-or-pcv21-under.md)
- [Cost-Effectiveness of Ensitrelvir Post-Exposure Prophylaxis for High-Risk Household Contacts in Ja](https://medichelpline.com/clinical-feed/medrxiv-0-cost-effectiveness-of-ensitrelvir-for-covid-19-post-exposure-prophylaxis-among.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years before diagnosis](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.